<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667794</url>
  </required_header>
  <id_info>
    <org_study_id>MBW-PH</org_study_id>
    <nct_id>NCT03667794</nct_id>
  </id_info>
  <brief_title>Evaluation of Novel Lung Function Parameters in Patients With Pulmonary Hypertension (PH)</brief_title>
  <official_title>Evaluation of Novel Lung Function Parameters in Patients With Pulmonary Hypertension (PH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universit채tsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universit채tsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Little is known about affection of small airways in patients with pulmonary hypertension as
      well as the ideal diagnostic approach. The investigators therefore aimed to evaluate novel or
      not widely used lung function tests for the evaluation of airway function in patients with
      PH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2015</start_date>
  <completion_date type="Actual">July 31, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>LCI</measure>
    <time_frame>30 minutes</time_frame>
    <description>between-group difference in lung clearance index (LCI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>D5-20</measure>
    <time_frame>30 minutes</time_frame>
    <description>between-group difference in frequency dependence of resistance (D5-20)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Discrimination small airway resistance</measure>
    <time_frame>30 minutes</time_frame>
    <description>Evaluation of discriminative capability of impulse oscillometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discrimination ventilation heterogeneity</measure>
    <time_frame>30 minutes</time_frame>
    <description>Evaluation of discriminative capability of multiple breath washout</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">75</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>PH patients</arm_group_label>
    <description>Patients with known or first diagnosis of PH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <description>Healthy controls had normal lung function testing including whole-body plethysmography and transfer factor, no previously diagnosed pulmonary disease as well as no respiratory symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-healthy controls</arm_group_label>
    <description>Non-healthy controls were allowed to have stable pulmonary comorbidities including chronic obstructive pulmonary disease (COPD), sarcoidosis, asthma, or fibrosis as well as non-pulmonary comorbidities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>body plethysmography</intervention_name>
    <description>measurement of conventional lung function parameters</description>
    <arm_group_label>PH patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>non-healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>impulse oscillometry</intervention_name>
    <description>measurement of central and peripheral airway resistance</description>
    <arm_group_label>PH patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>non-healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multiple breath washout</intervention_name>
    <description>measurement of ventilation heterogeneity</description>
    <arm_group_label>PH patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_label>non-healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        PH group: known or first diagnosis of PH

        Healthy controls: normal lung function testing including whole-body plethysmography and
        transfer factor, no previously diagnosed pulmonary disease as well as no respiratory
        symptoms.

        Non-healthy controls: stable pulmonary comorbidities including COPD, sarcoidosis, asthma,
        or fibrosis as well as non-pulmonary comorbidities.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  known or first diagnosis of PH

        Exclusion Criteria:

          -  inability to perform lung function testing

          -  unable or unwilling to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik Trinkmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit채tsmedizin Mannheim</affiliation>
  </overall_official>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universit채tsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Dr. Frederik Trinkmann</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

